EWTX
Edgewise Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$37.92
+1.96%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$37.41
From 52W high−21.57%
Volume1.37M
Market cap$4.12B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$37.41
From 52W high
−21.57%
Volume
1.37M
Market cap
$4.12B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−18.8x
P/E (TTM)
—
RSI (14)
40.0
MomentumView details →
1D Return
+1.96%
YTD Return
+52.01%
SummaryUpdated Jun 1, 2026
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Boulder, Colorado. The company went public in March 2021 and focuses on developing innovative small molecule therapies to treat rare musculoskeletal diseases. Edgewise specializes in precision medicine approaches targeting genetically defined muscle disorders, with their lead drug candidate currently in clinical development for treating devastating muscle-wasting diseases including Duchenne muscular dystrophy.
Similar companies
Latest newsMore news →
Edgewise Therapeutics dosed the first patient in its Phase 2 EQUINOX-HFpEF trial evaluating EDG-15400 in adults with symptomatic HFpEF and LVEF of at least 50%.12d agoEdgewise Therapeutics unveiled the differentiated mechanism of action of its cardiac sarcomere modulator EDG-7500, which targets the Regulatory Light Chain and improved cardiac relaxation while preserving systolic function in preclinical models.28d agoEdgewise Therapeutics reported a net loss of $57.3 million for Q2 2026, with R&D expenses of $47.5 million and G&A expenses of $14.4 million.75d ago